148 related articles for article (PubMed ID: 8694560)
1. UGP in urogenital disorders: Egyptian experience.
el-Ahmady O; Halim AB; Gad M; Walker R
Anticancer Res; 1996; 16(4B):2301-8. PubMed ID: 8694560
[TBL] [Abstract][Full Text] [Related]
2. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
3. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
[TBL] [Abstract][Full Text] [Related]
4. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
5. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
6. Assessment of urinary gonadotropin in solid carcinomas other than gynecological tumors.
von Kleist S; Walker B; Walker R
J Clin Lab Anal; 1996; 10(4):184-92. PubMed ID: 8811461
[TBL] [Abstract][Full Text] [Related]
7. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
[TBL] [Abstract][Full Text] [Related]
8. UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP.
Schwarz-Roeger U; Petzoldt B; Waldschmidt R; Walker RP; Bauknecht T; Kiechle M
Anticancer Res; 1997; 17(4B):3041-5. PubMed ID: 9329597
[TBL] [Abstract][Full Text] [Related]
9. Urinary gonadotropin peptide in patients with cancer of digestive organs.
Motoo Y; Watanabe H; Yamaguchi Y; Mouri I; Fujii T; Yamakawa O; Satomura Y; Okai T; Sawabu N
Anticancer Res; 1996; 16(4A):2041-8. PubMed ID: 8712740
[TBL] [Abstract][Full Text] [Related]
10. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its beta-subunit, and beta core fragment in the urine: application to malignancies.
O'Connor JF; Schlatterer JP; Birken S; Krichevsky A; Armstrong EG; McMahon D; Canfield RE
Cancer Res; 1988 Mar; 48(5):1361-6. PubMed ID: 2449279
[TBL] [Abstract][Full Text] [Related]
11. Following metastatic placental site trophoblastic tumor with urine beta-core fragment.
Rinne K; Shahabi S; Cole L
Gynecol Oncol; 1999 Aug; 74(2):302-3. PubMed ID: 10419751
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
Schwartz PE; Cracchiolo BM; Cole LA
Anticancer Res; 1996; 16(4B):2135-9. PubMed ID: 8694533
[TBL] [Abstract][Full Text] [Related]
13. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer].
Nishimura R; Kobayashi K; Katsuno M; Kobayashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):143-8. PubMed ID: 1690253
[TBL] [Abstract][Full Text] [Related]
14. Urinary gonadotropin peptide: collection of specimens and cutoff levels.
Plebani M; Navaglia F; Bacelle L; Polonio S; Lazzari F; Marchetti M
J Clin Lab Anal; 1995; 9(4):230-3. PubMed ID: 7562239
[TBL] [Abstract][Full Text] [Related]
15. [Urinary gonadotropin fragment measurement in the monitoring of trophoblastic disease].
Fu CY; Cole LA; Kardana A
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):475-7, 510-1. PubMed ID: 7835119
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)].
Radici E; Persiani P; Stroppa S; Lombardi PL; Torre GC
Minerva Ginecol; 1996; 48(1-2):5-9. PubMed ID: 8750482
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix.
Carter PG; Iles RK; Neven P; Ind TE; Shepherd JH; Chard T
Gynecol Oncol; 1994 Nov; 55(2):271-6. PubMed ID: 7525427
[TBL] [Abstract][Full Text] [Related]
18. Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease.
el-Ahmady O; Halim AB; Mansour O; Salman T; el-Din AG; Walker RP
Br J Cancer; 1996 Jun; 73(12):1486-90. PubMed ID: 8664117
[TBL] [Abstract][Full Text] [Related]
19. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.
el-Ahmady O; Halim AB; el-Din AG
Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202
[TBL] [Abstract][Full Text] [Related]
20. Cross-reaction with luteinizing hormone beta-core is responsible for the age-dependent increase of immunoreactive beta-core fragment of human chorionic gonadotropin in women with nonmalignant conditions.
Iles RK; Javid MK; Gunn LK; Chard T
Clin Chem; 1999 Apr; 45(4):532-8. PubMed ID: 10102914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]